Skip to content
Telehealth Graded
State guide

Alabama Medicaid and GLP-1s

The takeaway

Alabama added Wegovy to its preferred drug list in July 2026 with a footnote saying it isn't covered for weight loss; Zepbound is covered for sleep apnea.

Reading the state documents

Alabama's drug list carries both weight-management GLP-1s and a footnote under each that takes the weight indication back. Zepbound is preferred for obstructive sleep apnea with obesity and non-covered for weight reduction without it. Wegovy is available by authorization for cardiovascular risk and liver disease, and non-covered for weight reduction. The criteria document behind the footnotes requires no diagnosis of diabetes on any of these routes.

2
documents cited
6
sourced facts
2
primary sources

What changed, and what the document says

  1. Zepbound is preferred, for one diagnosis

    Conditions apply

    The footnote scopes the preferred status to a single indication rather than to the drug.

    “Zepbound is preferred with clinical criteria for”

    Alabama Medicaid Agency — Effective 07/01/2026

  2. And non-covered without it

    Not covered

    The second half of the same footnote is the refusal, in the list's own words.

    “Zepbound is non-covered for weight”

    Alabama Medicaid Agency — Effective 07/01/2026

  3. Wegovy carries the same sentence

    Not covered

    Alabama added Wegovy to the list effective July 2026 and excluded the weight indication in the same act.

    “Wegovy is non-covered for weight reduction.”

    Alabama Medicaid Agency — Effective 07/01/2026

  4. No diabetes diagnosis on these routes

    Conditions apply

    The criteria put the sleep-apnea threshold and the age floor in one sentence, and close it by excluding diabetes.

    “moderate to severe obstructive sleep apnea (apnea-hypopnea index [AHI] ≥15)”

    Alabama Medicaid Agency, Division of Pharmacy Services — Effective 07/01/2026

  5. Counseling, and no stacking

    Conditions apply

    Both conditions are in one attestation, so a prescriber confirms them together.

    “The patient has been counseled to continue a reduced-calorie diet and increased physical activity”

    Alabama Medicaid Agency, Division of Pharmacy Services — Effective 07/01/2026

  6. The liver route needs documentation of the indication

    Conditions apply

    Alabama's MASH pathway is conditioned on evidence for the labeled indication and, again, on not having diabetes.

    “with no diagnosis of diabetes.”

    Alabama Medicaid Agency, Division of Pharmacy Services — Effective 07/01/2026

Telehealth in Alabama

  • CCaveat
    $1,299
    a month, medication only
    brand Ozempic (semaglutide), cash price
    Additional fees not verified.
    Price details
    • No separate monthly fee was found in the pages reviewed. Other charges may apply.
    • Brand-name Ozempic, quoted as a cash price. Gala says insurance may reduce it and does not publish what it would reduce it to.
    See Gala Health pricing (opens in a new tab)

Some providers pay us a commission when you sign up through our links, at no extra cost to you.

Which of these companies serve Alabama?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

12 of those lists name Alabama: Gala Health, Care Bare Rx, TelePeptide, Ways2Well, TeleClinic, Tyde Wellness, Trimi, Rx.com, Mojoon, Peak Wellness, Allara Health, and Mixx Health & Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.

Sources

Source dates below are the dates printed on the documents.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.